161957-56-8

Basic information

• Product Name: 3-Bromo-2-fluorobenzoic acid
• Synonyms: 3-Bromo-2-fluorobenzoic acid 97%;Benzoic acid, 3-bromo-2-fluoro-;BUTTPARK 14\01-30;3-BROMO-2-FLUOROBENZOIC ACID;3-Bromo-2-fluorobenzoic;3-Bromo-2-fluorobenzoic acid 97%+
• CAS NO: 161957-56-8
• Molecular Formula: C₇H₄BrFO₂
• Molecular Weight: 219.01
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Benzoic acid;API intermediates;Acids and Derivatives;Halides
• Mol File: 161957-56-8.mol

Chemical Properties

• Melting Point: 168 °C
• Boiling Point: 298.2 °C at 760 mmHg
• Flash Point: 134.1 °C
• Appearance: white to off-white solid
• Density: 1.789 g/cm₃
• Vapor Pressure: 9.41mmHg at 25°C
• Refractive Index: 1.438
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.88±0.10(Predicted)
• CAS DataBase Reference: 3-Bromo-2-fluorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-2-fluorobenzoic acid(161957-56-8)
• EPA Substance Registry System: 3-Bromo-2-fluorobenzoic acid(161957-56-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 161957-56-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-2-fluorobenzoic acid is used as a reagent for the synthesis of Dabrafenib, a BRAF kinase inhibitor. 3-Bromo-2-fluorobenzoic acid is utilized in the treatment of BRAF V600-mutation positive carcinoma, as it targets the BRAF gene that plays a crucial role in cell growth and is often mutated in cancer cases.
Used in Allergy Treatment:
3-Bromo-2-fluorobenzoic acid is also used as a reagent to prepare Alkynlphenoxyacetic acid receptor agonists. These compounds have the potential to be used in the treatment of allergic inflammatory diseases, such as allergic rhinitis, by modulating the immune response and reducing inflammation.

InChI:InChI=1/C4H2Br2F4/c1-2(5)3(7,8)4(6,9)10/h1H2

Upstream product

• 1072-85-1 o-fluorobromobenzene 
• 124-38-9 carbon dioxide 
• 109-72-8 n-butyllithium 
• 206551-41-9 2-fluoro-3-bromobenzoic acid methyl ester 

Downstream Products

• 261723-32-4 1-bromo-2-fluoro-3-(hydroxymethyl)benzene 
• 334792-76-6 ethyl 3-bromo-2-fluorobenzoate 
• 680610-73-5 N-methoxy-N-methyl-3-bromo-2-fluorobenzamide 
• 334792-77-7 ethyl 2-fluoro-3-(4-hydroxypiperidin-1-yl)benzoate 
• 334792-80-2 ethyl 3-(4-aminopiperidin-1-yl)-2-fluorobenzoate 
• 334792-79-9 ethyl 3-(4-azidopiperidin-1-yl)-2-fluorobenzoate 
• 334792-78-8 Ethyl 2-fluoro-3-{(4-methanesulfonyloxy)piperidin-1-yl}benzoate 
• 334792-82-4 2-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoic acid 
• 334792-81-3 ethyl 2-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate 
• 334792-84-6 (2S)-benzenesulfonylamino-3-[2-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]-propionic acid 
• 334792-83-5 tert-butyl (2S)-benzenesulfonylamino-3-[2-fluoro-3-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 149947-16-0 1-bromo-3-(bromomethyl)-2-fluorobenzene 
• 447463-24-3 (3-{4-[1-(3-bromo-2-fluoro-benzyloxy)-ethyl]-2-methoxy-5-nitro-phenoxy}-propyl)-carbamic acid tert-butyl ester 
• 848440-23-3 (3-bromo-2-fluorophenyl)carbamic acid tert-butyl ester 

Relevant articles and documents

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

TRICYCLIC ASK1 INHIBITORS

Provided herein are compounds, preferably ASK1 inhibitor compounds, compositions thereof, and methods of their preparation, and methods of inhibiting ASK1 and methods for treating disorders mediated by ASK1.

TRPV4 ANTAGONISTS

The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

INHIBITORS OF STEAROYL-COA DESATURASE

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors

As a result of the various N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives with a hydroxy moiety synthesized in an effort to discover novel glycogen phosphorylase (GP) inhibitors, 5-chloro-N-(5-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-1H-indole-2

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part IV: Preliminary control of αvβ3 selectivity by meta-oriented substitution

To establish the in vivo efficacy of αvβ3/αIIbβ3 dual antagonists possessing a tricyclic pharmacophore, a corresponding αvβ3-selective antagonist was required as a control. We initially too